The 2026 peptide regulatory landscape: a plain-English map

The short version: peptide regulation in 2026 is in motion. Some compounds are accessible, some are not, and the line between them is being redrawn by the FDA, the courts, and the PCAC advisory committee.

TL;DR

• FDA's interim policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to Category 1 substances. Of the 19 peptides FDA added to Category 2 in 2023, only MK-677 and kisspeptin-10 remain there as of September 14, 2026.
• In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
• FDA's advisory committee voted on seven peptides on July 23–24, 2026. As of September 14, 2026, FDA has not made a final decision.

What the landscape is

The U.S. peptide regulatory landscape (in plain English: the set of FDA rules, court decisions, and advisory committee recommendations that determine which peptides can be prescribed and compounded) is built on three layers. The first layer is FDA approval — only a small number of peptides are FDA-approved as finished products (semaglutide, tirzepatide, sermorelin acetate when it was branded, bremelanotide as Vyleesi, tesamorelin). The second layer is compounding — state-licensed 503A pharmacies may compound certain peptides for individual patients. The third layer is enforcement — FDA warning letters, Federal Register notices, and court rulings shape what is happening on the ground.

How the system works

Think of the system as a three-light traffic signal. Green light: Category 1, FDA's list of substances under evaluation. FDA's interim policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to these, when other conditions are met. Non-injectable GHK-Cu is in Category 1. Red light: Category 2, FDA's list of substances that raise significant safety risks. As of September 14, 2026, MK-677 (ibutamoren) and kisspeptin-10 are the only peptides from FDA's 2023 additions still in Category 2. Yellow light: peptides that are in no FDA 503A category and are not on the bulks list. As of September 14, 2026, this group includes KPV, MOTS-c, DSIP, epitalon, melanotan-2, Selank, Semax, sermorelin, CJC-1295, ipamorelin, oxytocin, IGF-1 LR3, and injectable GHK-Cu. BPC-157 and TB-500 are in this group too: FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend adding each to the Section 503A bulk drug substances list, and FDA has not made a final decision. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. The FDA's compounding bulk-drug-substance list (FDA, 2026) is the official source.

Who is affected

Patients, prescribing physicians, and 503A pharmacies are all directly affected. About 1 in 6 longevity-focused medical practices reported having to change a patient's protocol after the 2023 Category 2 reclassification. The downstream effect — gray-market sourcing, inconsistent quality, prescriber confusion — is one reason ongoing regulatory clarity matters.

What changed in 2026

In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. On April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. On April 16, 2026, FDA published a Federal Register notice that scheduled the July advisory committee meeting (Federal Register portal). The Novo Nordisk v. Hims & Hers patent case, filed February 9, 2026, was voluntarily dismissed on March 9, 2026, and is closed. The PCAC met on July 23–24, 2026. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What to know before considering it

The legal status of any specific peptide should be confirmed at the time of prescribing — not assumed from a prior conversation. Compounded peptides are not FDA-approved. A licensed prescriber's evaluation is required.

The Halftime POV

The 2026 landscape is unsettled, and that is the most accurate sentence to write about it. Mapping the system honestly — not selling certainty that does not exist — is the only responsible posture.

Related reading:

• Category 1 vs Category 2 peptides: the access framework
• Secretary Kennedy's February 2026 peptide remarks
• What the July 2026 PCAC meeting could change

---

FAQ

Q: Are compounded peptides legal in 2026? A: Some are; some are not. FDA's interim policy of not taking action against compounding with a substance not yet on the 503A bulks list applies only to Category 1 substances, when other conditions are met. As of September 14, 2026, MK-677 (ibutamoren) and kisspeptin-10 remain in Category 2. Many other peptides, including BPC-157 and TB-500, are in no FDA 503A category and are not on the bulks list. The list shifts as the FDA reviews nominations and PCAC issues recommendations.

Q: What did Secretary Kennedy's February 2026 remarks do? A: It was not a formal action. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. On April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. As of September 14, 2026, those peptides are not in any FDA 503A category and are not on the 503A bulks list.

Q: Is the regulatory landscape still changing? A: Yes. The PCAC (Pharmacy Compounding Advisory Committee) met on July 23–24, 2026. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against emideltide (DSIP). The committee is advisory, and FDA's final decisions are pending as of September 2026. New Federal Register notices, court decisions, and warning letters continue to shape the picture month by month.

---

Disclaimer

Several peptides discussed in this article — including KPV, MOTS-c, DSIP, epitalon, melanotan-2, Selank, and Semax — were previously in FDA's Category 2. FDA removed them from Category 2 (September 2024 or April 2026, depending on the peptide). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
• Federal Register — Food and Drug Administration agency portal

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.